HDM1005 (poterepatide), a novel GLP-1/GIP dual agonist, achieves superior HbA1c reduction and weight loss over Tirzepatide.
Background
Effective management of Type 2 Diabetes Mellitus (T2DM) and obesity remains a significant challenge, with current therapies often falling short in efficacy or requiring frequent dosing. Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are established treatments, but dual agonists like Tirzepatide have shown enhanced metabolic benefits by targeting both GLP-1R and GIPR. There's a continuous need for compounds with improved potency, pharmacokinetics, and a more favorable safety profile to maximize glycemic control and weight loss while preserving lean mass.
Study Design
Researchers engineered HDM1005 (poterepatide), a novel GLP-1/GIP dual agonist, using computational alanine scanning and rational acylation design. Initially, nonacylated P001 was evaluated for receptor binding stability and affinity against nonacylated Tirzepatide via molecular dynamics simulations and MMGBSA calculations. Optimized linker and acyl chain designs at K24/28 acylation sites on P001 were then applied. The optimized HDM1005 was tested in vivo: for HbA1c reduction in db/db mice and for weight loss in DIO mice, comparing its efficacy against Tirzepatide. Pharmacokinetic properties, including T1/2, were also assessed in mice, alongside a safety profile evaluation to determine the NOAEL.
Results
Computational analysis showed nonacylated P001, the precursor to HDM1005, had stable receptor binding and higher affinity than nonacylated Tirzepatide. Optimized acylation design extended HDM1005's half-life (T1/2) to ∼ 20.3-23.1 h in mice, significantly longer than Tirzepatide's 9.21 h. In db/db mice, HDM1005 exerted 3-fold more potent HbA1c reduction compared to Tirzepatide. Obese DIO mice treated with HDM1005 demonstrated superior weight loss, achieving 39.97% reduction versus 34.47% with Tirzepatide. This weight loss was characterized by preferential fat loss with preservation of lean mass. Furthermore, HDM1005 exhibited a favorable safety profile, with a NOAEL of 5 mg/kg. HDM1005 achieved 3-fold greater HbA1c reduction and 39.97% weight loss, surpassing Tirzepatide's 34.47% in mouse models, alongside a significantly extended half-life.
Key Findings
- HDM1005 (poterepatide) was engineered as a novel high-potency GLP-1/GIP dual agonist.
- Nonacylated HDM1005 precursor showed higher receptor affinity than nonacylated Tirzepatide in simulations.
- HDM1005's half-life (T1/2) was extended to ∼ 20.3-23.1 h in mice, compared to Tirzepatide's 9.21 h.
- HDM1005 achieved 3-fold more potent HbA1c reduction in db/db mice than Tirzepatide.
- HDM1005 induced superior weight loss (39.97%) in DIO mice versus Tirzepatide (34.47%), preserving lean mass.
Why It Matters
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. For individuals struggling with Type 2 Diabetes and obesity, a compound with superior HbA1c reduction, greater weight loss, and lean mass preservation could lead to better long-term health outcomes and quality of life. The improved pharmacokinetic profile might translate to less frequent injections, enhancing patient adherence. This research paves the way for future clinical trials, bringing us closer to a potential best-in-class therapeutic agent that could redefine current treatment protocols for GLP-1/GIP dual agonists.